NCT03909334View on ClinicalTrials.gov

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Non Small Cell Lung CancerEGFR Gene MutationAdvanced CancerMetastatic Cancer
Interventions
DRUG

Osimertinib

Osimertinib 80 mg orally on Day 1

DRUG

Ramucirumab

Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes

Trial Locations (12)

10016

New York University Cancer Center, New York

10032

Columbia University Irving Medical Center, New York

20057

Georgetown University, Washington D.C.

22908

University of Virginia Health System, Charlottesville

33612

Moffitt Cancer Center, Tampa

46202

Indiana Univesity Melvin and Bren Simon Cancer Center, Indianapolis

60611

Northwestern University Feinberg School of Medicine, Chicago

60612

Rush University Medical Center, Chicago

77030

MD Anderson Cancer Center, Houston

97213

Providence Portland Medical Center, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

07922

Summit Medical Group, PA, Berkeley Heights

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

lead

Xiuning Le

OTHER

NCT03909334 - Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter